Novocure (NVCR) Reports Q3 Loss of $2.09/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Novocure Reports Third Quarter 2015 Operating and Financial Results
October 26, 2015 4:05 PM EDTFDA approved Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma on October 5, 2015
CE Mark was placed on the second generation Optune system. First patients treated in Europe with the newly designed, smaller, lighter system
468 active patients at quarter end, an increase of 161% versus the prior year quarter end
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, today reported operating and financial results for the three and nine months ended September 30, 2015.
... More
